Joanna Edwards’ Post

Please join me and many other Medical Affairs experts at the 16th annual #MedAffairs #Transformation conference on November 14 in Zurich, Switzerland. I'll share my perspectives on 'the impact of medical affairs on the corporate's mid and long-term strategy' and join a panel session to discuss 'the Impact of internal and external stakeholder value needs on Medical Affairs capabilities development' Please learn more about the program and find out how to register below. Looking forward to engaging discussions and catching up with friends! #ViaViatris #EvidenceLifeScience

We are thrilled to announce that Market Access Today is officially partnering with the World Evidence, Pricing and Access Congress 2025! Scheduled for March 5-6 at the RAI Congress Centre in Amsterdam, this event is set to be Europe's largest congress in market access, pricing, and evidence, featuring over 250 speakers and welcoming more than 1,500 attendees from the pharmaceutical, biotech, and payer sectors. As we expand the dialogue in healthcare, Market Access Today is proud to stand alongside esteemed solution providers like Valid Insight (part of the Bioscript Group), RxData, Lifescience Dynamics Limited, and Parexel. Together, we'll explore core topics such as Market Access and Pricing, Rare Diseases, and HTA/Payer dynamics, while delving into the latest trends in reimbursement, payment models, and HEOR. We're immensely grateful for the warm congratulations and flattering messages from the event representatives and our community. Your support energizes our commitment to driving innovation and leadership in healthcare. Let's make a transformative impact at the World Evidence, Pricing and Access Congress 2025. Join us as we help shape the future of healthcare. For more information and to register, please visit World Evidence, Pricing and Access Congress 2025: https://lnkd.in/dnbYK3Ft #EPAConf #heor #health #pricing #reimbursement #healtheconomics #healthpolicy #marketaccess #pharmaceuticals #rarediseases #payer 

The transformation of pharma from an industry perceived as one putting profit before people to one with patients front and center is underway, but we still need to accelerate partnerships to reach the ultimate end goal. Download Reuters brand new white paper to learn more: https://bit.ly/3WEv9N4 Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

The transformation of pharma from an industry perceived as one putting profit before people to one with patients front and center is underway, but we still need to accelerate partnerships to reach the ultimate end goal. Download Reuters brand new white paper to learn more: https://bit.ly/4c6NdnB Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

The transformation of pharma from an industry perceived as one putting profit before people to one with patients front and center is underway, but we still need to accelerate partnerships to reach the ultimate end goal. Download Reuters brand new white paper to learn more: https://bit.ly/3A3EHbw Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!

Great interview with Paul Kirchmeier from Alex Therapeutics about how it is to work with Pharma and which business models works best for a DTx solution. Watch the video on Allis Health the digital health analyst platform

🍯 Everyone is looking for the holy grail for successful Pharma and Startup partnerships. The truth is, that there is no one size fits all! Paul Kirchmeier and I agree on the fact that both partners need to be a good fit in the context of product life cycle, business model and strategy. ❓ What is your key success factor for a fruitful partnership? #dtx #digitalhealthcare #partnerships Allis Health Ignited Vision by Susanne Gruber

💥 Join us for our first webinar of 2024 as we discuss the value of digital measures in drug development 💊🧪 with Maulik Majmudar, Ariel Dowling and Erwin De beuckelaer. 👀 We’ll take a look at insights from our latest report with Biofourmis and ask, how can we come together to ensure better utilisation of digital measures in clinical trials? During the webinar we’ll discuss: 💬 What are the biggest barriers to the adoption of digital endpoints in drug development? 💬 What is required to shift towards using digital measures as primary endpoints and supporting label claims in the future? 💬 Where does it make sense to leverage digital endpoints and for what purpose? Register now ➡️ https://lnkd.in/e5eFMVEB #drugdevelopment #digitalmeasures #digitalhealth

WHEN WILL CLINICAL DEVELOPMENT COSTS BE ADDRESSED ..WHEN UNLIMITED US PRICING OF DRUGS CEASES Everything about the costs in the pharmaceutical industry is opaque, that is fully intentional. Everyone takes overpriced advantage in an "honor among thieves" fashion with "the sucker," i.e. taxpayers/insurance premium payers footing the bill for this monopoly. Global Pharma's US predatory pricing model is ending, costs of drug development will come fully under the microscope and the type of quantitative price modeling and project cost management that this emerging company (Strategikon Pharma) offers will become essential. #pharma #pharmaceuticals #clinicaldevelopment #clinicaltrials #drugpricing #strategikonpharma AREhttps://lnkd.in/ewastvjR